Cargando…

Turoctocog alfa (NovoEight®) – from design to clinical proof of concept

Turoctocog alfa (NovoEight®) is a recombinant factor VIII (rFVIII) with a truncated B-domain made from the sequence coding for 10 amino acids from the N-terminus and 11 amino acids from the C-terminus of the naturally occurring B-domain. Turoctocog alfa is produced in Chinese hamster ovary (CHO) cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ezban, Mirella, Vad, Knud, Kjalke, Marianne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Review Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232928/ https://www.ncbi.nlm.nih.gov/pubmed/24797664 http://dx.doi.org/10.1111/ejh.12366

Ejemplares similares

Molecular design and downstream processing of turoctocog alfa (NovoEight), a B-domain truncated factor VIII molecule
por: Ahmadian, Haleh, et al.
Publicado: (2016)

An overview of turoctocog alfa pegol (N8‐GP; ESPEROCT(®)) assay performance: Implications for postadministration monitoring
por: Ezban, Mirella, et al.
Publicado: (2019)

Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials
por: Santagostino, E, et al.
Publicado: (2015)

Recombinant FVIII Products (Turoctocog Alfa and Turoctocog Alfa Pegol) Stable Up to 40°C
por: Napolitano, Mariasanta, et al.
Publicado: (2021)

The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A
por: Napolitano, Mariasanta, et al.
Publicado: (2019)

Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A
por: Takedani, Hideyuki, et al.
Publicado: (2015)

Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A
por: Vashi, Parth, et al.
Publicado: (2021)

Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results
por: John, M. Joseph, et al.
Publicado: (2020)

Stability of Turoctocog Alfa, a Recombinant Factor VIII Product, during Continuous Infusion In Vitro
por: Takeyama, Masahiro, et al.
Publicado: (2020)

The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A
por: Male, Christoph, et al.
Publicado: (2022)

Illustrative Cases from the Pathfinder Clinical Trials of Patients with Hemophilia A Treated with Turoctocog Alfa Pegol (N8-GP)
por: Klamroth, Robert, et al.
Publicado: (2021)

Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa
por: Santagostino, E, et al.
Publicado: (2014)

Reagent‐specific underestimation of turoctocog alfa pegol (N8‐GP) clotting activity owing to decelerated activation by thrombin
por: Persson, Egon, et al.
Publicado: (2018)

Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
por: Klamroth, Robert, et al.
Publicado: (2019)

Plasma Polyethylene Glycol (PEG) Levels Reach Steady State Following Repeated Treatment with N8-GP (Turoctocog Alfa Pegol; Esperoct(®))
por: Bjørnsdottir, Inga, et al.
Publicado: (2020)

Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial
por: Yaish, Hassan, et al.
Publicado: (2019)

Real-World Experience of People with Hemophilia A Receiving Turoctocog Alfa Pegol (N8-GP): Results from a Patient Experience Survey
por: Eichler, Hermann, et al.
Publicado: (2023)

Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
por: Wu, Runhui, et al.
Publicado: (2020)

Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study
por: Lentz, Steven R., et al.
Publicado: (2022)

Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII‐treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2021)

Immuno-PET: Design options and clinical proof-of-concept
por: Lugat, Alexandre, et al.
Publicado: (2022)

Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII
por: Kearney, Susan, et al.
Publicado: (2019)

Designing and conducting proof-of-concept chronic pain analgesic clinical trials
por: Campbell, Claudia M., et al.
Publicado: (2019)

Proof of Concept to Clinical Confirmation: Evolving Clinical Trial Designs for Targeted Agents
por: Finn, Laura, et al.
Publicado: (2012)

Garments for functional electrical stimulation: Design and proofs of concept
por: Moineau, Bastien, et al.
Publicado: (2019)

Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials
por: Tosetto, Alberto, et al.
Publicado: (2020)

Gold Nanotheranostics: Proof-of-Concept or Clinical Tool?
por: Pedrosa, Pedro, et al.
Publicado: (2015)

Design of a fully intraureteral stent and proof-of-concept in vivo evaluation
por: Shilo, Yaniv, et al.
Publicado: (2022)

Myocardial Viability: From Proof of Concept to Clinical Practice
por: Bhat, Aditya, et al.
Publicado: (2016)

The Versatile Transceiver Proof of Concept
por: Troska, J, et al.
Publicado: (2009)

A field study evaluating the activity of N8‐GP in spiked plasma samples at clinical haemostasis laboratories
por: Tiefenbacher, Stefan, et al.
Publicado: (2019)

Dietary algae and HIV/AIDS: proof of concept clinical data
por: Teas, J., et al.
Publicado: (2011)

Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses
por: Kjalke, Marianne, et al.
Publicado: (2021)

ALFA
por: Hiller, Karlheinz
Publicado: (2012)

The LHCb Grid simulation: Proof of concept
por: Hushchyn, M, et al.
Publicado: (2017)

DNA watermarks: A proof of concept
por: Heider, Dominik, et al.
Publicado: (2008)

Groupness in Preverbal Infants: Proof of Concept
por: Bradley, Benjamin Sylvester, et al.
Publicado: (2017)

Design and Test of a Biosensor-Based Multisensorial System: A Proof of Concept Study
por: Santonico, Marco, et al.
Publicado: (2013)

Safe-by-Design Antibacterial Peroxide-Substituted Biomimetic Apatites: Proof of Concept in Tropical Dentistry
por: Ana, Ika Dewi, et al.
Publicado: (2022)

Design, Construction and Metrology of the Overlap Detectors for the ALFA system
por: Braem, André, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_0huvu6r8tshrqj6nsq1q91gad4